Literature DB >> 1354234

Divalent cation substitution reveals CD18- and very late antigen-dependent pathways that mediate human neutrophil adherence to fibronectin.

J F Bohnsack1, X N Zhou.   

Abstract

We investigated the mechanisms by which Mn2+ alters human neutrophil (PMN) adherence to various connective tissue proteins. Substitution of Mn2+ for Ca2+ and Mg2+ significantly increased adhesion of human PMN to plastic well coated with fibronectin, fibrinogen, and laminin but not gelatin. Anti-CD18 mAb almost completely blocked adherence to laminin, partly blocked adherence to fibrinogen, but did not inhibit adhesion to fibronectin at all. In contrast, anti-very late antigen (VLA)-5 mAb antibodies significantly reduced Mn(2+)-mediated PMN adherence to fibronectin, but not to laminin or fibrinogen, demonstrating that VLA-5-mediated PMN adherence to fibronectin, but not to fibrinogen or laminin. This was supported by experiments in which synthetic GRGDSP peptide significantly inhibited Mn(2+)-mediated adherence to fibronectin, but not to laminin or fibrinogen. Activation of PMN with phorbol ester or C5a stimulated VLA-5-mediated adhesion to fibronectin, but the contribution of VLA-5 to the forces mediating adherence could only be detected when CD18 function was either blocked with mAb, or when CD18 was congenitally absent. VLA-5 mediated adhesion was also more transient than CD18-dependent adhesion. These data further confirm the presence of PMN VLA integrins and demonstrate that PMN VLA-5 contributes to stimulated PMN adherence to fibronectin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354234

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Comparative effects of antilactoferrin antibodies and tumor necrosis factor on neutrophil adherence to matrix proteins.

Authors:  B Zweiman; C von Allmen
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Yersinia pseudotuberculosis-induced calcium signaling in neutrophils is blocked by the virulence effector YopH.

Authors:  K Andersson; K E Magnusson; M Majeed; O Stendahl; M Fällman
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Mac-1 (CD11b/CD18) is the predominant beta 2 (CD18) integrin mediating human neutrophil migration through synovial and dermal fibroblast barriers.

Authors:  J X Gao; A C Issekutz
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  Integrin expression on neutrophils in a rabbit model of Group B Streptococcal meningitis.

Authors:  M E Rowin; V Xue; J Irazuzta
Journal:  Inflammation       Date:  2000-04       Impact factor: 4.092

5.  The beta 1 integrin, very late activation antigen-4 on human neutrophils can contribute to neutrophil migration through connective tissue fibroblast barriers.

Authors:  J X Gao; A C Issekutz
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

6.  Beta 2 (CD18) and beta 1 (CD29) integrin mechanisms in migration of human polymorphonuclear leucocytes and monocytes through lung fibroblast barriers: shared and distinct mechanisms.

Authors:  X Z Shang; A C Issekutz
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

Review 7.  The impact of metal availability on immune function during infection.

Authors:  Andrew J Monteith; Eric P Skaar
Journal:  Trends Endocrinol Metab       Date:  2021-09-03       Impact factor: 12.015

8.  Polymorphonuclear leucocyte migration through human dermal fibroblast monolayers is dependent on both beta 2-integrin (CD11/CD18) and beta 1-integrin (CD29) mechanisms.

Authors:  J X Gao; A C Issekutz
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

9.  Cytoprotective effects of a cyclic RGD peptide in steatotic liver cold ischemia and reperfusion injury.

Authors:  C Fondevila; X-D Shen; S Duarte; R W Busuttil; A J Coito
Journal:  Am J Transplant       Date:  2009-07-22       Impact factor: 8.086

10.  beta1 integrins are critically involved in neutrophil locomotion in extravascular tissue In vivo.

Authors:  J Werr; X Xie; P Hedqvist; E Ruoslahti; L Lindbom
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.